Comparison of Core Biopsy and Excision Materials in Terms of Histological Type, Histological Grade, Hormone Receptors, and Human Epidermal Growth Factor Receptor 2 Expression in Invasive Breast Carcinomas

demir, hale; Demirhan Onaygil, Emel; ilvan, Sennur

doi:10.5505/tjo.2022.3451

Comparison of Core Biopsy and Excision Materials in Terms of Histological Type, Histological Grade, Hormone Receptors, and Human Epidermal Growth Factor Receptor 2 Expression in Invasive Breast Carcinomas

Emel DEMİRHAN ONAYGİL, (Helios Klinikum Emil von Behring, Department of Pathology, Berlin, Germany)

Hale DEMİR, (Amasya Üniversitesi, Tıp Fakültesi, Patoloji Anabilim Dalı, Amasya, Türkiye)

Şennur İLVAN (İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Patoloji Anabilim Dalı, İstanbul, Türkiye)

Türk Onkoloji Dergisi

0 0

Yıl: 2022 Cilt: 37 Sayı: 3 Sayfa Aralığı: 267 - 276 Metin Dili: İngilizce DOI: 10.5505/tjo.2022.3451 İndeks Tarihi: 05-05-2023

Comparison of Core Biopsy and Excision Materials in Terms of Histological Type, Histological Grade, Hormone Receptors, and Human Epidermal Growth Factor Receptor 2 Expression in Invasive Breast Carcinomas

Öz:

Pre-operative diagnosis using core biopsy (CB) is one of the goals of the current approach for breast cancer, to learn the biological behavior of the tumor and reduce the costs by appropriate treatment planning. METHODS The histologic type, grade, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status of 201 patients were recorded for both the CB and excision specimens and compared with each other. RESULTS When we compared both materials, we found 89% concordance for histologic type and 75% for grade. There was a strong concordance for ER, PR, and HER2 status (96%, 89%, and 96%, respectively). CONCLUSION Higher rates of ER, PR, and HER2 positivity in core biopsies may be related to easier fixation, shorter unfixed time, or taking the CB from the tumor periphery. The CB is a reliable tool for pre-operative diagnosis and management of the breast cancer treatment. However, because of the CB may not represent the entire tumor, final decision for histologic type and grade should be made on excision specimens. Although it is low, the discordance rates in terms of hormone receptor (HR) and HER2 expression between two materials should be considered. If there is a discordance between histological type/grade and HR/HER2 status, especially in HR and HER2 negative cases, these studies should be repeated in the excision material. Internal and external controls should be used during immunohistochemical study, attention should be paid during fixation.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11–30.
2. Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, et al; National Comprehensive Cancer Network. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2013;11(7):753–60; quiz 761.
3. Litherland JC, Evans AJ, Wilson AR, Kollias J, Pinder SE, Elston CW, et al. The impact of core-biopsy on preoperative diagnosis rate of screen detected breast cancers. Clin Radiol 1996;51(8):562–5.
4. Rakha EA, Ellis IO. An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens. J Clin Pathol 2007;60(12):1300–6.
5. Park SY, Kim KS, Lee TG, Park SS, Kim SM, Han W, et al. The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer. Am J Surg 2009;197(2):266–9.
6. Richter-Ehrenstein C, Müller S, Noske A, Schneider A. Diagnostic accuracy and prognostic value of core biopsy in the management of breast cancer: a series of 542 patients. Int J Surg Pathol 2009;17(4):323–6.
7. Crowe JP Jr, Patrick RJ, Rybicki LA, Grundfest SF, Kim JA, Lee KB, et al. Does ultrasound core breast biopsy predict histologic finding on excisional biopsy? Am J Surg 2003;186(4):397–9.
8. Zhu S, Wu J, Huang O, He J, Zhu L, Li Y, et al. clinicopathological features and disease outcome in breast cancer patients with hormonal receptor discordance between core needle biopsy and following surgical sample. Ann Surg Oncol 2019;26(9):2779–86.
9. Ough M, Velasco J, Hieken TJ. A comparative analysis of core needle biopsy and final excision for breast cancer: histology and marker expression. Am J Surg 2011;201(5):692–4.
10. Badoual C, Maruani A, Ghorra C, Lebas P, Avigdor S, Michenet P. Pathological prognostic factors of invasive breast carcinoma in ultrasound-guided large core biopsies-correlation with subsequent surgical excisions. Breast 2005;14(1):22–7.
11. Burge CN, Chang HR, Apple SK. Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens? Breast 2006;15(2):167–72.
12. Greer LT, Rosman M, Mylander WC, Hooke J, Kovatich A, Sawyer K, et al. Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens? J Am Coll Surg 2013;216(2):239–51.
13. Lorgis V, Algros MP, Villanueva C, Chaigneau L, Thierry- Vuillemin A, Nguyen T, et al. Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor- 2 status between core needle biopsy and surgical excisional primary tumour. Breast 2011;20(3):284–7.
14. Uy GB, Laudico AV, Carnate JM Jr, Lim FG, Fernandez AM, Rivera RR, et al. Breast cancer hormone receptor assay results of core needle biopsy and modified radical mastectomy specimens from the same patients. Clin Breast Cancer 2010;10(2):154–9.
15. Rakha EA, Allison KH, Ellis IO, Horii R, Masuda S, Penault-Llorca F, et al. Invasive breast carcinoma. In: Allison KH, Brogi E, Ellis IO, Fox SB, Morris EA, Sahin A, editors. WHO Classification of Tumours. 5th ed. Breast Tumours. Lyon: IARC; 2019. p. 82–138.
16. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with longterm follow-up. Histopathology 2002;41:154–61.
17. Fitzgibbons PL, Dillon DA, Alsabeh R, Berman MA, Hayes DF, Hicks DG, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. Arch Pathol Lab Med 2014;138:595–601.
18. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 2014;138(2):241–56.
19. Dawson-Saunders B, Trapp Robert G. Research questions about two seperate or independent groups. In: Dawson-Saunders B, Trapp Robert G, editors. Basic & Clinical Biostatistic. New York: Lange Medical Books / McGraw-Hill; 2004. p. 134–62.
20. Verkooijen HM; Core Biopsy After Radiological Localisation (COBRA) Study Group. Diagnostic accuracy of stereotactic large-core needle biopsy for nonpalpable breast disease: results of a multicenter prospective study with 95% surgical confirmation. Int J Cancer 2002;99(6):853–9.
21. Verkooijen HM, Peeters PH, Buskens E, Koot VC, Borel Rinkes IH, Mali WP, et al. Diagnostic accuracy of large-core needle biopsy for nonpalpable breast disease: a meta-analysis. Br J Cancer 2000;82(5):1017–21.
22. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart- Gebhart M, Thürlimann B, et al; Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013;24(9):2206–23.
23. Early Breast Cancer Trialists’ Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient- level meta-analysis of randomised trials. Lancet 2011;378(9793):771–84.
24. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365(14):1273–83.
25. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379(9814):432–44.
26. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784–95.
27. Asogan AB, Hong GS, Arni Prabhakaran SK. Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer. Singapore Med J 2017;58(3):145–9.
28. Qiu J, Kulkarni S, Chandrasekhar R, Rees M, Hyde K, Wilding G, et al. Effect of delayed formalin fixation on estrogen and progesterone receptors in breast cancer: a study of three different clones. Am J Clin Pathol 2010;134(5):813–9.
29. Yildiz-Aktas IZ, Dabbs DJ, Bhargava R. The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Mod Pathol 2012;25(8):1098–105.
30. Werner M, Chott A, Fabiano A, Battifora H. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol 2000;24(7):1016–9.
31. Douglas-Jones AG, Collett N, Morgan JM, Jasani B. Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma. J Clin Pathol 2001;54(12):951–5.
32. Zidan A, Christie Brown JS, Peston D, Shousha S. Oestrogen and progesterone receptor assessment in core biopsy specimens of breast carcinoma. J Clin Pathol 1997;50(1):27–9.
33. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, et al. Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94(11):852–4.
34. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002;94(11):855–7.
35. Usami S, Moriya T, Amari M, Suzuki A, Ishida T, Sasano H, et al. Reliability of prognostic factors in breast carcinoma determined by core needle biopsy. Jpn J Clin Oncol 2007;37(4):250–5.
36. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012;12(5):323–34
37. Mueller-Holzner E, Fink V, Frede T, Marth C. Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: a reliable predictor of HER2 status of the whole tumor. Breast Cancer Res Treat 2001;69(1):13–9.
38. Shousha S, Peston D, Amo-Takyi B, Morgan M, Jasani B. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. Histopathology 2009;54(2):248–53.

APA	Demirhan Onaygil E, demir h, ilvan S (2022). Comparison of Core Biopsy and Excision Materials in Terms of Histological Type, Histological Grade, Hormone Receptors, and Human Epidermal Growth Factor Receptor 2 Expression in Invasive Breast Carcinomas. , 267 - 276. 10.5505/tjo.2022.3451
Chicago	Demirhan Onaygil Emel,demir hale,ilvan Sennur Comparison of Core Biopsy and Excision Materials in Terms of Histological Type, Histological Grade, Hormone Receptors, and Human Epidermal Growth Factor Receptor 2 Expression in Invasive Breast Carcinomas. (2022): 267 - 276. 10.5505/tjo.2022.3451
MLA	Demirhan Onaygil Emel,demir hale,ilvan Sennur Comparison of Core Biopsy and Excision Materials in Terms of Histological Type, Histological Grade, Hormone Receptors, and Human Epidermal Growth Factor Receptor 2 Expression in Invasive Breast Carcinomas. , 2022, ss.267 - 276. 10.5505/tjo.2022.3451
AMA	Demirhan Onaygil E,demir h,ilvan S Comparison of Core Biopsy and Excision Materials in Terms of Histological Type, Histological Grade, Hormone Receptors, and Human Epidermal Growth Factor Receptor 2 Expression in Invasive Breast Carcinomas. . 2022; 267 - 276. 10.5505/tjo.2022.3451
Vancouver	Demirhan Onaygil E,demir h,ilvan S Comparison of Core Biopsy and Excision Materials in Terms of Histological Type, Histological Grade, Hormone Receptors, and Human Epidermal Growth Factor Receptor 2 Expression in Invasive Breast Carcinomas. . 2022; 267 - 276. 10.5505/tjo.2022.3451
IEEE	Demirhan Onaygil E,demir h,ilvan S "Comparison of Core Biopsy and Excision Materials in Terms of Histological Type, Histological Grade, Hormone Receptors, and Human Epidermal Growth Factor Receptor 2 Expression in Invasive Breast Carcinomas." , ss.267 - 276, 2022. 10.5505/tjo.2022.3451
ISNAD	Demirhan Onaygil, Emel vd. "Comparison of Core Biopsy and Excision Materials in Terms of Histological Type, Histological Grade, Hormone Receptors, and Human Epidermal Growth Factor Receptor 2 Expression in Invasive Breast Carcinomas". (2022), 267-276. https://doi.org/10.5505/tjo.2022.3451

APA	Demirhan Onaygil E, demir h, ilvan S (2022). Comparison of Core Biopsy and Excision Materials in Terms of Histological Type, Histological Grade, Hormone Receptors, and Human Epidermal Growth Factor Receptor 2 Expression in Invasive Breast Carcinomas. Türk Onkoloji Dergisi, 37(3), 267 - 276. 10.5505/tjo.2022.3451
Chicago	Demirhan Onaygil Emel,demir hale,ilvan Sennur Comparison of Core Biopsy and Excision Materials in Terms of Histological Type, Histological Grade, Hormone Receptors, and Human Epidermal Growth Factor Receptor 2 Expression in Invasive Breast Carcinomas. Türk Onkoloji Dergisi 37, no.3 (2022): 267 - 276. 10.5505/tjo.2022.3451
MLA	Demirhan Onaygil Emel,demir hale,ilvan Sennur Comparison of Core Biopsy and Excision Materials in Terms of Histological Type, Histological Grade, Hormone Receptors, and Human Epidermal Growth Factor Receptor 2 Expression in Invasive Breast Carcinomas. Türk Onkoloji Dergisi, vol.37, no.3, 2022, ss.267 - 276. 10.5505/tjo.2022.3451
AMA	Demirhan Onaygil E,demir h,ilvan S Comparison of Core Biopsy and Excision Materials in Terms of Histological Type, Histological Grade, Hormone Receptors, and Human Epidermal Growth Factor Receptor 2 Expression in Invasive Breast Carcinomas. Türk Onkoloji Dergisi. 2022; 37(3): 267 - 276. 10.5505/tjo.2022.3451
Vancouver	Demirhan Onaygil E,demir h,ilvan S Comparison of Core Biopsy and Excision Materials in Terms of Histological Type, Histological Grade, Hormone Receptors, and Human Epidermal Growth Factor Receptor 2 Expression in Invasive Breast Carcinomas. Türk Onkoloji Dergisi. 2022; 37(3): 267 - 276. 10.5505/tjo.2022.3451
IEEE	Demirhan Onaygil E,demir h,ilvan S "Comparison of Core Biopsy and Excision Materials in Terms of Histological Type, Histological Grade, Hormone Receptors, and Human Epidermal Growth Factor Receptor 2 Expression in Invasive Breast Carcinomas." Türk Onkoloji Dergisi, 37, ss.267 - 276, 2022. 10.5505/tjo.2022.3451
ISNAD	Demirhan Onaygil, Emel vd. "Comparison of Core Biopsy and Excision Materials in Terms of Histological Type, Histological Grade, Hormone Receptors, and Human Epidermal Growth Factor Receptor 2 Expression in Invasive Breast Carcinomas". Türk Onkoloji Dergisi 37/3 (2022), 267-276. https://doi.org/10.5505/tjo.2022.3451